(NU/1433-27) iFAST: The Provision of Business Consultancy to Assist Commercialisation of University Research.

The emergence of bacteria that are resistant to antibiotics is a growing public health problem. In 2015, there were nearly 700,0000 antimicrobial resistance (AMR) infections in the EU, accounting for 33,000 deaths and 900,000 disability-adjusted life years (DALYs) . In fact the impact of AMR is similar to the combined burden of influenza, tuberculosis, and HIV, and the global increases in healthcare costs is forecast to range from $300 billion to more than $1 trillion per year by 2050.

We have developed a breakthrough technology that delivers an antibiotic resistance test result in 1 hour. The technique rapidly measures phenotypic changes in bacteria after exposure to antibiotics.

The objective is for the Executive (CEO Desig) to jointly work in a team with all above named individuals to bring the opportunity towards and ultimately achieve launch of a new spinout company.